nodes	percent_of_prediction	percent_of_DWPC	metapath
Mycophenolate mofetil—Mycophenolic acid—systemic scleroderma	0.424	1	CrCtD
Mycophenolate mofetil—systemic lupus erythematosus—systemic scleroderma	0.145	0.558	CtDrD
Mycophenolate mofetil—psoriasis—systemic scleroderma	0.114	0.442	CtDrD
Mycophenolate mofetil—UGT1A7—Mycophenolic acid—systemic scleroderma	0.0751	0.302	CbGbCtD
Mycophenolate mofetil—IMPDH2—Mycophenolic acid—systemic scleroderma	0.0543	0.219	CbGbCtD
Mycophenolate mofetil—IMPDH1—Mycophenolic acid—systemic scleroderma	0.0432	0.174	CbGbCtD
Mycophenolate mofetil—UGT1A6—Mycophenolic acid—systemic scleroderma	0.0312	0.126	CbGbCtD
Mycophenolate mofetil—UGT1A9—Mycophenolic acid—systemic scleroderma	0.0091	0.0366	CbGbCtD
Mycophenolate mofetil—UGT2B7—Mycophenolic acid—systemic scleroderma	0.00861	0.0346	CbGbCtD
Mycophenolate mofetil—UGT1A1—Mycophenolic acid—systemic scleroderma	0.00744	0.0299	CbGbCtD
Mycophenolate mofetil—ABCG2—Leflunomide—systemic scleroderma	0.0037	0.0149	CbGbCtD
Mycophenolate mofetil—CYP2C8—Mometasone—systemic scleroderma	0.00306	0.0123	CbGbCtD
Mycophenolate mofetil—ALB—Captopril—systemic scleroderma	0.002	0.00806	CbGbCtD
Mycophenolate mofetil—SLCO1B3—Methotrexate—systemic scleroderma	0.00198	0.00798	CbGbCtD
Mycophenolate mofetil—ABCB1—Lisinopril—systemic scleroderma	0.0014	0.00563	CbGbCtD
Mycophenolate mofetil—ALB—Prednisone—systemic scleroderma	0.00126	0.00507	CbGbCtD
Mycophenolate mofetil—SLCO1B1—Methotrexate—systemic scleroderma	0.00115	0.00465	CbGbCtD
Mycophenolate mofetil—ABCB1—Captopril—systemic scleroderma	0.00105	0.00421	CbGbCtD
Mycophenolate mofetil—ABCC2—Methotrexate—systemic scleroderma	0.00101	0.00408	CbGbCtD
Mycophenolate mofetil—ABCG2—Methotrexate—systemic scleroderma	0.000917	0.00369	CbGbCtD
Mycophenolate mofetil—ABCB1—Prednisone—systemic scleroderma	0.000659	0.00265	CbGbCtD
Mycophenolate mofetil—ALB—Methotrexate—systemic scleroderma	0.000632	0.00254	CbGbCtD
Mycophenolate mofetil—UGT1A7—digestive system—systemic scleroderma	0.000555	0.0849	CbGeAlD
Mycophenolate mofetil—UGT1A10—digestive system—systemic scleroderma	0.000464	0.071	CbGeAlD
Mycophenolate mofetil—UGT1A6—digestive system—systemic scleroderma	0.000432	0.066	CbGeAlD
Mycophenolate mofetil—CYP3A4—Prednisone—systemic scleroderma	0.000395	0.00159	CbGbCtD
Mycophenolate mofetil—UGT1A8—digestive system—systemic scleroderma	0.000367	0.0561	CbGeAlD
Mycophenolate mofetil—ABCB1—Methotrexate—systemic scleroderma	0.000331	0.00133	CbGbCtD
Mycophenolate mofetil—IMPDH2—smooth muscle tissue—systemic scleroderma	0.000262	0.04	CbGeAlD
Mycophenolate mofetil—IMPDH1—smooth muscle tissue—systemic scleroderma	0.00026	0.0398	CbGeAlD
Mycophenolate mofetil—IMPDH2—skin of body—systemic scleroderma	0.000258	0.0395	CbGeAlD
Mycophenolate mofetil—CES2—smooth muscle tissue—systemic scleroderma	0.000238	0.0364	CbGeAlD
Mycophenolate mofetil—CES2—skin of body—systemic scleroderma	0.000235	0.0359	CbGeAlD
Mycophenolate mofetil—UGT1A9—digestive system—systemic scleroderma	0.000233	0.0356	CbGeAlD
Mycophenolate mofetil—CES1—connective tissue—systemic scleroderma	0.000214	0.0328	CbGeAlD
Mycophenolate mofetil—IMPDH2—digestive system—systemic scleroderma	0.000207	0.0316	CbGeAlD
Mycophenolate mofetil—IMPDH2—tendon—systemic scleroderma	0.000197	0.0301	CbGeAlD
Mycophenolate mofetil—IMPDH1—tendon—systemic scleroderma	0.000196	0.0299	CbGeAlD
Mycophenolate mofetil—SLCO1B3—lung—systemic scleroderma	0.000192	0.0293	CbGeAlD
Mycophenolate mofetil—CES2—digestive system—systemic scleroderma	0.000188	0.0287	CbGeAlD
Mycophenolate mofetil—UGT2B7—digestive system—systemic scleroderma	0.000188	0.0287	CbGeAlD
Mycophenolate mofetil—CES2—tendon—systemic scleroderma	0.000179	0.0273	CbGeAlD
Mycophenolate mofetil—IMPDH2—lung—systemic scleroderma	0.000173	0.0264	CbGeAlD
Mycophenolate mofetil—IMPDH1—lung—systemic scleroderma	0.000172	0.0262	CbGeAlD
Mycophenolate mofetil—UGT1A1—digestive system—systemic scleroderma	0.00016	0.0244	CbGeAlD
Mycophenolate mofetil—CES2—lung—systemic scleroderma	0.000157	0.024	CbGeAlD
Mycophenolate mofetil—CES1—digestive system—systemic scleroderma	0.000155	0.0237	CbGeAlD
Mycophenolate mofetil—SLCO1B1—digestive system—systemic scleroderma	0.000133	0.0203	CbGeAlD
Mycophenolate mofetil—CES1—lung—systemic scleroderma	0.000129	0.0198	CbGeAlD
Mycophenolate mofetil—ABCC2—digestive system—systemic scleroderma	0.000101	0.0154	CbGeAlD
Mycophenolate mofetil—ABCB1—blood vessel—systemic scleroderma	9.79e-05	0.015	CbGeAlD
Mycophenolate mofetil—ABCC2—tendon—systemic scleroderma	9.59e-05	0.0147	CbGeAlD
Mycophenolate mofetil—CYP3A5—digestive system—systemic scleroderma	6.82e-05	0.0104	CbGeAlD
Mycophenolate mofetil—ABCG2—lung—systemic scleroderma	6.14e-05	0.00938	CbGeAlD
Mycophenolate mofetil—CYP3A5—lung—systemic scleroderma	5.7e-05	0.00871	CbGeAlD
Mycophenolate mofetil—CYP3A4—digestive system—systemic scleroderma	5.12e-05	0.00783	CbGeAlD
Mycophenolate mofetil—ABCB1—digestive system—systemic scleroderma	3.62e-05	0.00554	CbGeAlD
Mycophenolate mofetil—ABCB1—lung—systemic scleroderma	3.03e-05	0.00463	CbGeAlD
Mycophenolate mofetil—Asthenia—Captopril—systemic scleroderma	1.45e-05	0.000236	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Mometasone—systemic scleroderma	1.45e-05	0.000236	CcSEcCtD
Mycophenolate mofetil—Decreased appetite—Leflunomide—systemic scleroderma	1.45e-05	0.000236	CcSEcCtD
Mycophenolate mofetil—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	1.45e-05	0.000236	CcSEcCtD
Mycophenolate mofetil—Osteoarthritis—Methotrexate—systemic scleroderma	1.45e-05	0.000236	CcSEcCtD
Mycophenolate mofetil—Confusional state—Lisinopril—systemic scleroderma	1.45e-05	0.000235	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Azathioprine—systemic scleroderma	1.45e-05	0.000235	CcSEcCtD
Mycophenolate mofetil—Headache—Mometasone—systemic scleroderma	1.44e-05	0.000235	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal disorder—Leflunomide—systemic scleroderma	1.44e-05	0.000234	CcSEcCtD
Mycophenolate mofetil—Insomnia—Mycophenolic acid—systemic scleroderma	1.44e-05	0.000234	CcSEcCtD
Mycophenolate mofetil—Anaphylactic shock—Lisinopril—systemic scleroderma	1.43e-05	0.000233	CcSEcCtD
Mycophenolate mofetil—Oedema—Lisinopril—systemic scleroderma	1.43e-05	0.000233	CcSEcCtD
Mycophenolate mofetil—Pruritus—Captopril—systemic scleroderma	1.43e-05	0.000233	CcSEcCtD
Mycophenolate mofetil—Paraesthesia—Mycophenolic acid—systemic scleroderma	1.43e-05	0.000233	CcSEcCtD
Mycophenolate mofetil—Pain—Leflunomide—systemic scleroderma	1.43e-05	0.000232	CcSEcCtD
Mycophenolate mofetil—Constipation—Leflunomide—systemic scleroderma	1.43e-05	0.000232	CcSEcCtD
Mycophenolate mofetil—Infection—Lisinopril—systemic scleroderma	1.43e-05	0.000232	CcSEcCtD
Mycophenolate mofetil—Dyspnoea—Mycophenolic acid—systemic scleroderma	1.42e-05	0.000231	CcSEcCtD
Mycophenolate mofetil—Somnolence—Mycophenolic acid—systemic scleroderma	1.42e-05	0.00023	CcSEcCtD
Mycophenolate mofetil—Shock—Lisinopril—systemic scleroderma	1.41e-05	0.000229	CcSEcCtD
Mycophenolate mofetil—Thrombocytopenia—Lisinopril—systemic scleroderma	1.4e-05	0.000228	CcSEcCtD
Mycophenolate mofetil—Dyspepsia—Mycophenolic acid—systemic scleroderma	1.4e-05	0.000228	CcSEcCtD
Mycophenolate mofetil—Neutropenia—Prednisone—systemic scleroderma	1.4e-05	0.000228	CcSEcCtD
Mycophenolate mofetil—Tachycardia—Lisinopril—systemic scleroderma	1.4e-05	0.000228	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Azathioprine—systemic scleroderma	1.4e-05	0.000227	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Azathioprine—systemic scleroderma	1.4e-05	0.000227	CcSEcCtD
Mycophenolate mofetil—Skin disorder—Lisinopril—systemic scleroderma	1.39e-05	0.000227	CcSEcCtD
Mycophenolate mofetil—Hyperhidrosis—Lisinopril—systemic scleroderma	1.39e-05	0.000225	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Captopril—systemic scleroderma	1.39e-05	0.000225	CcSEcCtD
Mycophenolate mofetil—Decreased appetite—Mycophenolic acid—systemic scleroderma	1.38e-05	0.000225	CcSEcCtD
Mycophenolate mofetil—Erectile dysfunction—Prednisone—systemic scleroderma	1.38e-05	0.000224	CcSEcCtD
Mycophenolate mofetil—Feeling abnormal—Leflunomide—systemic scleroderma	1.38e-05	0.000224	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	1.37e-05	0.000224	CcSEcCtD
Mycophenolate mofetil—Mood swings—Methotrexate—systemic scleroderma	1.37e-05	0.000223	CcSEcCtD
Mycophenolate mofetil—Nausea—Mometasone—systemic scleroderma	1.37e-05	0.000223	CcSEcCtD
Mycophenolate mofetil—Anorexia—Lisinopril—systemic scleroderma	1.37e-05	0.000222	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Leflunomide—systemic scleroderma	1.37e-05	0.000222	CcSEcCtD
Mycophenolate mofetil—Weight increased—Prednisone—systemic scleroderma	1.36e-05	0.000222	CcSEcCtD
Mycophenolate mofetil—Pain—Mycophenolic acid—systemic scleroderma	1.36e-05	0.000221	CcSEcCtD
Mycophenolate mofetil—Constipation—Mycophenolic acid—systemic scleroderma	1.36e-05	0.000221	CcSEcCtD
Mycophenolate mofetil—Weight decreased—Prednisone—systemic scleroderma	1.36e-05	0.00022	CcSEcCtD
Mycophenolate mofetil—Hyperglycaemia—Prednisone—systemic scleroderma	1.35e-05	0.00022	CcSEcCtD
Mycophenolate mofetil—Hypotension—Lisinopril—systemic scleroderma	1.34e-05	0.000218	CcSEcCtD
Mycophenolate mofetil—Dizziness—Captopril—systemic scleroderma	1.34e-05	0.000218	CcSEcCtD
Mycophenolate mofetil—Liver function test abnormal—Methotrexate—systemic scleroderma	1.34e-05	0.000217	CcSEcCtD
Mycophenolate mofetil—Depression—Prednisone—systemic scleroderma	1.33e-05	0.000217	CcSEcCtD
Mycophenolate mofetil—Urticaria—Leflunomide—systemic scleroderma	1.33e-05	0.000216	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Leflunomide—systemic scleroderma	1.32e-05	0.000215	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Leflunomide—systemic scleroderma	1.32e-05	0.000215	CcSEcCtD
Mycophenolate mofetil—Acute coronary syndrome—Prednisone—systemic scleroderma	1.32e-05	0.000214	CcSEcCtD
Mycophenolate mofetil—Feeling abnormal—Mycophenolic acid—systemic scleroderma	1.31e-05	0.000213	CcSEcCtD
Mycophenolate mofetil—Neuropathy peripheral—Prednisone—systemic scleroderma	1.31e-05	0.000213	CcSEcCtD
Mycophenolate mofetil—Myocardial infarction—Prednisone—systemic scleroderma	1.31e-05	0.000213	CcSEcCtD
Mycophenolate mofetil—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	1.31e-05	0.000212	CcSEcCtD
Mycophenolate mofetil—Hypersensitivity—Azathioprine—systemic scleroderma	1.3e-05	0.000212	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	1.3e-05	0.000212	CcSEcCtD
Mycophenolate mofetil—Insomnia—Lisinopril—systemic scleroderma	1.3e-05	0.000211	CcSEcCtD
Mycophenolate mofetil—Paraesthesia—Lisinopril—systemic scleroderma	1.29e-05	0.000209	CcSEcCtD
Mycophenolate mofetil—Vomiting—Captopril—systemic scleroderma	1.29e-05	0.000209	CcSEcCtD
Mycophenolate mofetil—Dyspnoea—Lisinopril—systemic scleroderma	1.28e-05	0.000208	CcSEcCtD
Mycophenolate mofetil—Rash—Captopril—systemic scleroderma	1.28e-05	0.000208	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Captopril—systemic scleroderma	1.28e-05	0.000207	CcSEcCtD
Mycophenolate mofetil—Somnolence—Lisinopril—systemic scleroderma	1.28e-05	0.000207	CcSEcCtD
Mycophenolate mofetil—Headache—Captopril—systemic scleroderma	1.27e-05	0.000206	CcSEcCtD
Mycophenolate mofetil—Dyspepsia—Lisinopril—systemic scleroderma	1.26e-05	0.000205	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Mycophenolic acid—systemic scleroderma	1.26e-05	0.000205	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Mycophenolic acid—systemic scleroderma	1.26e-05	0.000205	CcSEcCtD
Mycophenolate mofetil—Asthma—Methotrexate—systemic scleroderma	1.25e-05	0.000204	CcSEcCtD
Mycophenolate mofetil—Decreased appetite—Lisinopril—systemic scleroderma	1.25e-05	0.000203	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal disorder—Lisinopril—systemic scleroderma	1.24e-05	0.000201	CcSEcCtD
Mycophenolate mofetil—Hypersensitivity—Leflunomide—systemic scleroderma	1.23e-05	0.0002	CcSEcCtD
Mycophenolate mofetil—Pancreatitis—Methotrexate—systemic scleroderma	1.23e-05	0.0002	CcSEcCtD
Mycophenolate mofetil—Pain—Lisinopril—systemic scleroderma	1.23e-05	0.000199	CcSEcCtD
Mycophenolate mofetil—Constipation—Lisinopril—systemic scleroderma	1.23e-05	0.000199	CcSEcCtD
Mycophenolate mofetil—Bradycardia—Prednisone—systemic scleroderma	1.22e-05	0.000198	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Azathioprine—systemic scleroderma	1.21e-05	0.000197	CcSEcCtD
Mycophenolate mofetil—Haemoglobin—Prednisone—systemic scleroderma	1.21e-05	0.000196	CcSEcCtD
Mycophenolate mofetil—Nausea—Captopril—systemic scleroderma	1.2e-05	0.000196	CcSEcCtD
Mycophenolate mofetil—Haemorrhage—Prednisone—systemic scleroderma	1.2e-05	0.000195	CcSEcCtD
Mycophenolate mofetil—Asthenia—Leflunomide—systemic scleroderma	1.2e-05	0.000195	CcSEcCtD
Mycophenolate mofetil—Hallucination—Prednisone—systemic scleroderma	1.19e-05	0.000194	CcSEcCtD
Mycophenolate mofetil—Pancytopenia—Methotrexate—systemic scleroderma	1.19e-05	0.000193	CcSEcCtD
Mycophenolate mofetil—Feeling abnormal—Lisinopril—systemic scleroderma	1.18e-05	0.000192	CcSEcCtD
Mycophenolate mofetil—Pruritus—Leflunomide—systemic scleroderma	1.18e-05	0.000192	CcSEcCtD
Mycophenolate mofetil—Connective tissue disorder—Prednisone—systemic scleroderma	1.18e-05	0.000192	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Lisinopril—systemic scleroderma	1.17e-05	0.000191	CcSEcCtD
Mycophenolate mofetil—Dysuria—Methotrexate—systemic scleroderma	1.17e-05	0.00019	CcSEcCtD
Mycophenolate mofetil—Neutropenia—Methotrexate—systemic scleroderma	1.17e-05	0.00019	CcSEcCtD
Mycophenolate mofetil—Dizziness—Azathioprine—systemic scleroderma	1.17e-05	0.00019	CcSEcCtD
Mycophenolate mofetil—Erectile dysfunction—Methotrexate—systemic scleroderma	1.15e-05	0.000187	CcSEcCtD
Mycophenolate mofetil—Asthenia—Mycophenolic acid—systemic scleroderma	1.14e-05	0.000186	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Leflunomide—systemic scleroderma	1.14e-05	0.000186	CcSEcCtD
Mycophenolate mofetil—Urticaria—Lisinopril—systemic scleroderma	1.14e-05	0.000185	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Lisinopril—systemic scleroderma	1.13e-05	0.000184	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Lisinopril—systemic scleroderma	1.13e-05	0.000184	CcSEcCtD
Mycophenolate mofetil—Pruritus—Mycophenolic acid—systemic scleroderma	1.13e-05	0.000183	CcSEcCtD
Mycophenolate mofetil—Vomiting—Azathioprine—systemic scleroderma	1.12e-05	0.000183	CcSEcCtD
Mycophenolate mofetil—Pneumonia—Methotrexate—systemic scleroderma	1.12e-05	0.000183	CcSEcCtD
Mycophenolate mofetil—Eye disorder—Prednisone—systemic scleroderma	1.12e-05	0.000182	CcSEcCtD
Mycophenolate mofetil—Infestation—Methotrexate—systemic scleroderma	1.12e-05	0.000182	CcSEcCtD
Mycophenolate mofetil—Infestation NOS—Methotrexate—systemic scleroderma	1.12e-05	0.000182	CcSEcCtD
Mycophenolate mofetil—Rash—Azathioprine—systemic scleroderma	1.11e-05	0.000181	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Azathioprine—systemic scleroderma	1.11e-05	0.000181	CcSEcCtD
Mycophenolate mofetil—Depression—Methotrexate—systemic scleroderma	1.11e-05	0.000181	CcSEcCtD
Mycophenolate mofetil—Headache—Azathioprine—systemic scleroderma	1.11e-05	0.00018	CcSEcCtD
Mycophenolate mofetil—Dizziness—Leflunomide—systemic scleroderma	1.1e-05	0.000179	CcSEcCtD
Mycophenolate mofetil—Renal failure—Methotrexate—systemic scleroderma	1.1e-05	0.000178	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Mycophenolic acid—systemic scleroderma	1.09e-05	0.000177	CcSEcCtD
Mycophenolate mofetil—Stomatitis—Methotrexate—systemic scleroderma	1.09e-05	0.000177	CcSEcCtD
Mycophenolate mofetil—Angiopathy—Prednisone—systemic scleroderma	1.09e-05	0.000177	CcSEcCtD
Mycophenolate mofetil—Conjunctivitis—Methotrexate—systemic scleroderma	1.09e-05	0.000176	CcSEcCtD
Mycophenolate mofetil—Arrhythmia—Prednisone—systemic scleroderma	1.07e-05	0.000174	CcSEcCtD
Mycophenolate mofetil—Sweating—Methotrexate—systemic scleroderma	1.07e-05	0.000174	CcSEcCtD
Mycophenolate mofetil—Haematuria—Methotrexate—systemic scleroderma	1.06e-05	0.000173	CcSEcCtD
Mycophenolate mofetil—Vomiting—Leflunomide—systemic scleroderma	1.06e-05	0.000173	CcSEcCtD
Mycophenolate mofetil—Alopecia—Prednisone—systemic scleroderma	1.06e-05	0.000172	CcSEcCtD
Mycophenolate mofetil—Hypersensitivity—Lisinopril—systemic scleroderma	1.06e-05	0.000172	CcSEcCtD
Mycophenolate mofetil—Hepatobiliary disease—Methotrexate—systemic scleroderma	1.06e-05	0.000172	CcSEcCtD
Mycophenolate mofetil—Dizziness—Mycophenolic acid—systemic scleroderma	1.05e-05	0.000171	CcSEcCtD
Mycophenolate mofetil—Epistaxis—Methotrexate—systemic scleroderma	1.05e-05	0.000171	CcSEcCtD
Mycophenolate mofetil—Rash—Leflunomide—systemic scleroderma	1.05e-05	0.000171	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Leflunomide—systemic scleroderma	1.05e-05	0.000171	CcSEcCtD
Mycophenolate mofetil—Mental disorder—Prednisone—systemic scleroderma	1.05e-05	0.000171	CcSEcCtD
Mycophenolate mofetil—Nausea—Azathioprine—systemic scleroderma	1.05e-05	0.000171	CcSEcCtD
Mycophenolate mofetil—Headache—Leflunomide—systemic scleroderma	1.05e-05	0.00017	CcSEcCtD
Mycophenolate mofetil—Malnutrition—Prednisone—systemic scleroderma	1.04e-05	0.00017	CcSEcCtD
Mycophenolate mofetil—Agranulocytosis—Methotrexate—systemic scleroderma	1.04e-05	0.000169	CcSEcCtD
Mycophenolate mofetil—Asthenia—Lisinopril—systemic scleroderma	1.03e-05	0.000167	CcSEcCtD
Mycophenolate mofetil—Pruritus—Lisinopril—systemic scleroderma	1.01e-05	0.000165	CcSEcCtD
Mycophenolate mofetil—Vomiting—Mycophenolic acid—systemic scleroderma	1.01e-05	0.000165	CcSEcCtD
Mycophenolate mofetil—Haemoglobin—Methotrexate—systemic scleroderma	1.01e-05	0.000164	CcSEcCtD
Mycophenolate mofetil—Rash—Mycophenolic acid—systemic scleroderma	1e-05	0.000163	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Mycophenolic acid—systemic scleroderma	1e-05	0.000163	CcSEcCtD
Mycophenolate mofetil—Haemorrhage—Methotrexate—systemic scleroderma	1e-05	0.000163	CcSEcCtD
Mycophenolate mofetil—Hepatitis—Methotrexate—systemic scleroderma	1e-05	0.000163	CcSEcCtD
Mycophenolate mofetil—Headache—Mycophenolic acid—systemic scleroderma	9.98e-06	0.000162	CcSEcCtD
Mycophenolate mofetil—Pharyngitis—Methotrexate—systemic scleroderma	9.95e-06	0.000162	CcSEcCtD
Mycophenolate mofetil—Nausea—Leflunomide—systemic scleroderma	9.92e-06	0.000161	CcSEcCtD
Mycophenolate mofetil—Urinary tract disorder—Methotrexate—systemic scleroderma	9.9e-06	0.000161	CcSEcCtD
Mycophenolate mofetil—Urethral disorder—Methotrexate—systemic scleroderma	9.82e-06	0.00016	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Lisinopril—systemic scleroderma	9.81e-06	0.00016	CcSEcCtD
Mycophenolate mofetil—Ill-defined disorder—Prednisone—systemic scleroderma	9.69e-06	0.000157	CcSEcCtD
Mycophenolate mofetil—Visual impairment—Methotrexate—systemic scleroderma	9.66e-06	0.000157	CcSEcCtD
Mycophenolate mofetil—Anaemia—Prednisone—systemic scleroderma	9.65e-06	0.000157	CcSEcCtD
Mycophenolate mofetil—Agitation—Prednisone—systemic scleroderma	9.59e-06	0.000156	CcSEcCtD
Mycophenolate mofetil—Angioedema—Prednisone—systemic scleroderma	9.54e-06	0.000155	CcSEcCtD
Mycophenolate mofetil—Dizziness—Lisinopril—systemic scleroderma	9.49e-06	0.000154	CcSEcCtD
Mycophenolate mofetil—Nausea—Mycophenolic acid—systemic scleroderma	9.46e-06	0.000154	CcSEcCtD
Mycophenolate mofetil—Malaise—Prednisone—systemic scleroderma	9.41e-06	0.000153	CcSEcCtD
Mycophenolate mofetil—Vertigo—Prednisone—systemic scleroderma	9.38e-06	0.000152	CcSEcCtD
Mycophenolate mofetil—Eye disorder—Methotrexate—systemic scleroderma	9.37e-06	0.000152	CcSEcCtD
Mycophenolate mofetil—Syncope—Prednisone—systemic scleroderma	9.36e-06	0.000152	CcSEcCtD
Mycophenolate mofetil—Tinnitus—Methotrexate—systemic scleroderma	9.34e-06	0.000152	CcSEcCtD
Mycophenolate mofetil—Cardiac disorder—Methotrexate—systemic scleroderma	9.3e-06	0.000151	CcSEcCtD
Mycophenolate mofetil—Loss of consciousness—Prednisone—systemic scleroderma	9.18e-06	0.000149	CcSEcCtD
Mycophenolate mofetil—Vomiting—Lisinopril—systemic scleroderma	9.12e-06	0.000148	CcSEcCtD
Mycophenolate mofetil—Angiopathy—Methotrexate—systemic scleroderma	9.09e-06	0.000148	CcSEcCtD
Mycophenolate mofetil—Rash—Lisinopril—systemic scleroderma	9.04e-06	0.000147	CcSEcCtD
Mycophenolate mofetil—Convulsion—Prednisone—systemic scleroderma	9.04e-06	0.000147	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Lisinopril—systemic scleroderma	9.04e-06	0.000147	CcSEcCtD
Mycophenolate mofetil—Mediastinal disorder—Methotrexate—systemic scleroderma	9.03e-06	0.000147	CcSEcCtD
Mycophenolate mofetil—Hypertension—Prednisone—systemic scleroderma	9.01e-06	0.000147	CcSEcCtD
Mycophenolate mofetil—Chills—Methotrexate—systemic scleroderma	8.99e-06	0.000146	CcSEcCtD
Mycophenolate mofetil—Headache—Lisinopril—systemic scleroderma	8.99e-06	0.000146	CcSEcCtD
Mycophenolate mofetil—Myalgia—Prednisone—systemic scleroderma	8.89e-06	0.000144	CcSEcCtD
Mycophenolate mofetil—Arthralgia—Prednisone—systemic scleroderma	8.89e-06	0.000144	CcSEcCtD
Mycophenolate mofetil—Anxiety—Prednisone—systemic scleroderma	8.86e-06	0.000144	CcSEcCtD
Mycophenolate mofetil—Alopecia—Methotrexate—systemic scleroderma	8.86e-06	0.000144	CcSEcCtD
Mycophenolate mofetil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.83e-06	0.000144	CcSEcCtD
Mycophenolate mofetil—Discomfort—Prednisone—systemic scleroderma	8.78e-06	0.000143	CcSEcCtD
Mycophenolate mofetil—Mental disorder—Methotrexate—systemic scleroderma	8.78e-06	0.000143	CcSEcCtD
Mycophenolate mofetil—Malnutrition—Methotrexate—systemic scleroderma	8.72e-06	0.000142	CcSEcCtD
Mycophenolate mofetil—Dysgeusia—Methotrexate—systemic scleroderma	8.54e-06	0.000139	CcSEcCtD
Mycophenolate mofetil—Nausea—Lisinopril—systemic scleroderma	8.52e-06	0.000139	CcSEcCtD
Mycophenolate mofetil—Oedema—Prednisone—systemic scleroderma	8.52e-06	0.000139	CcSEcCtD
Mycophenolate mofetil—Anaphylactic shock—Prednisone—systemic scleroderma	8.52e-06	0.000139	CcSEcCtD
Mycophenolate mofetil—Infection—Prednisone—systemic scleroderma	8.46e-06	0.000138	CcSEcCtD
Mycophenolate mofetil—Back pain—Methotrexate—systemic scleroderma	8.44e-06	0.000137	CcSEcCtD
Mycophenolate mofetil—Shock—Prednisone—systemic scleroderma	8.38e-06	0.000136	CcSEcCtD
Mycophenolate mofetil—Nervous system disorder—Prednisone—systemic scleroderma	8.36e-06	0.000136	CcSEcCtD
Mycophenolate mofetil—Tachycardia—Prednisone—systemic scleroderma	8.31e-06	0.000135	CcSEcCtD
Mycophenolate mofetil—Skin disorder—Prednisone—systemic scleroderma	8.28e-06	0.000135	CcSEcCtD
Mycophenolate mofetil—Hyperhidrosis—Prednisone—systemic scleroderma	8.24e-06	0.000134	CcSEcCtD
Mycophenolate mofetil—Anorexia—Prednisone—systemic scleroderma	8.12e-06	0.000132	CcSEcCtD
Mycophenolate mofetil—Ill-defined disorder—Methotrexate—systemic scleroderma	8.09e-06	0.000132	CcSEcCtD
Mycophenolate mofetil—Anaemia—Methotrexate—systemic scleroderma	8.06e-06	0.000131	CcSEcCtD
Mycophenolate mofetil—Malaise—Methotrexate—systemic scleroderma	7.87e-06	0.000128	CcSEcCtD
Mycophenolate mofetil—Vertigo—Methotrexate—systemic scleroderma	7.84e-06	0.000127	CcSEcCtD
Mycophenolate mofetil—Leukopenia—Methotrexate—systemic scleroderma	7.81e-06	0.000127	CcSEcCtD
Mycophenolate mofetil—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.76e-06	0.000126	CcSEcCtD
Mycophenolate mofetil—Insomnia—Prednisone—systemic scleroderma	7.71e-06	0.000125	CcSEcCtD
Mycophenolate mofetil—Paraesthesia—Prednisone—systemic scleroderma	7.65e-06	0.000124	CcSEcCtD
Mycophenolate mofetil—Cough—Methotrexate—systemic scleroderma	7.61e-06	0.000124	CcSEcCtD
Mycophenolate mofetil—Convulsion—Methotrexate—systemic scleroderma	7.56e-06	0.000123	CcSEcCtD
Mycophenolate mofetil—Dyspepsia—Prednisone—systemic scleroderma	7.5e-06	0.000122	CcSEcCtD
Mycophenolate mofetil—Chest pain—Methotrexate—systemic scleroderma	7.43e-06	0.000121	CcSEcCtD
Mycophenolate mofetil—Myalgia—Methotrexate—systemic scleroderma	7.43e-06	0.000121	CcSEcCtD
Mycophenolate mofetil—Arthralgia—Methotrexate—systemic scleroderma	7.43e-06	0.000121	CcSEcCtD
Mycophenolate mofetil—Decreased appetite—Prednisone—systemic scleroderma	7.41e-06	0.00012	CcSEcCtD
Mycophenolate mofetil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	7.38e-06	0.00012	CcSEcCtD
Mycophenolate mofetil—Discomfort—Methotrexate—systemic scleroderma	7.34e-06	0.000119	CcSEcCtD
Mycophenolate mofetil—Constipation—Prednisone—systemic scleroderma	7.29e-06	0.000118	CcSEcCtD
Mycophenolate mofetil—Confusional state—Methotrexate—systemic scleroderma	7.18e-06	0.000117	CcSEcCtD
Mycophenolate mofetil—Anaphylactic shock—Methotrexate—systemic scleroderma	7.12e-06	0.000116	CcSEcCtD
Mycophenolate mofetil—Infection—Methotrexate—systemic scleroderma	7.07e-06	0.000115	CcSEcCtD
Mycophenolate mofetil—Feeling abnormal—Prednisone—systemic scleroderma	7.02e-06	0.000114	CcSEcCtD
Mycophenolate mofetil—Nervous system disorder—Methotrexate—systemic scleroderma	6.98e-06	0.000114	CcSEcCtD
Mycophenolate mofetil—Thrombocytopenia—Methotrexate—systemic scleroderma	6.97e-06	0.000113	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Prednisone—systemic scleroderma	6.97e-06	0.000113	CcSEcCtD
Mycophenolate mofetil—Skin disorder—Methotrexate—systemic scleroderma	6.92e-06	0.000112	CcSEcCtD
Mycophenolate mofetil—Hyperhidrosis—Methotrexate—systemic scleroderma	6.88e-06	0.000112	CcSEcCtD
Mycophenolate mofetil—Anorexia—Methotrexate—systemic scleroderma	6.79e-06	0.00011	CcSEcCtD
Mycophenolate mofetil—Urticaria—Prednisone—systemic scleroderma	6.77e-06	0.00011	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Prednisone—systemic scleroderma	6.73e-06	0.00011	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Prednisone—systemic scleroderma	6.73e-06	0.00011	CcSEcCtD
Mycophenolate mofetil—Hypotension—Methotrexate—systemic scleroderma	6.65e-06	0.000108	CcSEcCtD
Mycophenolate mofetil—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.49e-06	0.000105	CcSEcCtD
Mycophenolate mofetil—Insomnia—Methotrexate—systemic scleroderma	6.44e-06	0.000105	CcSEcCtD
Mycophenolate mofetil—Paraesthesia—Methotrexate—systemic scleroderma	6.39e-06	0.000104	CcSEcCtD
Mycophenolate mofetil—Dyspnoea—Methotrexate—systemic scleroderma	6.35e-06	0.000103	CcSEcCtD
Mycophenolate mofetil—Somnolence—Methotrexate—systemic scleroderma	6.33e-06	0.000103	CcSEcCtD
Mycophenolate mofetil—Hypersensitivity—Prednisone—systemic scleroderma	6.28e-06	0.000102	CcSEcCtD
Mycophenolate mofetil—Dyspepsia—Methotrexate—systemic scleroderma	6.27e-06	0.000102	CcSEcCtD
Mycophenolate mofetil—Decreased appetite—Methotrexate—systemic scleroderma	6.19e-06	0.000101	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal disorder—Methotrexate—systemic scleroderma	6.15e-06	9.99e-05	CcSEcCtD
Mycophenolate mofetil—Asthenia—Prednisone—systemic scleroderma	6.11e-06	9.94e-05	CcSEcCtD
Mycophenolate mofetil—Pain—Methotrexate—systemic scleroderma	6.09e-06	9.9e-05	CcSEcCtD
Mycophenolate mofetil—Pruritus—Prednisone—systemic scleroderma	6.03e-06	9.8e-05	CcSEcCtD
Mycophenolate mofetil—Feeling abnormal—Methotrexate—systemic scleroderma	5.87e-06	9.54e-05	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Prednisone—systemic scleroderma	5.83e-06	9.48e-05	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.82e-06	9.47e-05	CcSEcCtD
Mycophenolate mofetil—Urticaria—Methotrexate—systemic scleroderma	5.66e-06	9.2e-05	CcSEcCtD
Mycophenolate mofetil—Dizziness—Prednisone—systemic scleroderma	5.63e-06	9.16e-05	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Methotrexate—systemic scleroderma	5.63e-06	9.15e-05	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Methotrexate—systemic scleroderma	5.63e-06	9.15e-05	CcSEcCtD
Mycophenolate mofetil—Vomiting—Prednisone—systemic scleroderma	5.42e-06	8.81e-05	CcSEcCtD
Mycophenolate mofetil—Rash—Prednisone—systemic scleroderma	5.37e-06	8.73e-05	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Prednisone—systemic scleroderma	5.37e-06	8.73e-05	CcSEcCtD
Mycophenolate mofetil—Headache—Prednisone—systemic scleroderma	5.34e-06	8.68e-05	CcSEcCtD
Mycophenolate mofetil—Hypersensitivity—Methotrexate—systemic scleroderma	5.25e-06	8.53e-05	CcSEcCtD
Mycophenolate mofetil—Asthenia—Methotrexate—systemic scleroderma	5.11e-06	8.31e-05	CcSEcCtD
Mycophenolate mofetil—Nausea—Prednisone—systemic scleroderma	5.06e-06	8.23e-05	CcSEcCtD
Mycophenolate mofetil—Pruritus—Methotrexate—systemic scleroderma	5.04e-06	8.19e-05	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Methotrexate—systemic scleroderma	4.87e-06	7.92e-05	CcSEcCtD
Mycophenolate mofetil—Dizziness—Methotrexate—systemic scleroderma	4.71e-06	7.66e-05	CcSEcCtD
Mycophenolate mofetil—Vomiting—Methotrexate—systemic scleroderma	4.53e-06	7.36e-05	CcSEcCtD
Mycophenolate mofetil—Rash—Methotrexate—systemic scleroderma	4.49e-06	7.3e-05	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Methotrexate—systemic scleroderma	4.49e-06	7.29e-05	CcSEcCtD
Mycophenolate mofetil—Headache—Methotrexate—systemic scleroderma	4.46e-06	7.25e-05	CcSEcCtD
Mycophenolate mofetil—Nausea—Methotrexate—systemic scleroderma	4.23e-06	6.88e-05	CcSEcCtD
